Medicenna’s Bizaxofusp Boosts Brain Cancer Survival
Company Announcements

Medicenna’s Bizaxofusp Boosts Brain Cancer Survival

Medicenna Therapeutics Corp (TSE:MDNA) has released an update.

Medicenna Therapeutics Corp. has presented promising clinical data at the ASCO 2024 showing that its drug, bizaxofusp, significantly increases survival rates for patients with recurrent glioblastoma. Compared to a matched external control, bizaxofusp nearly doubled the median overall survival time and halved the risk of death. These results support bizaxofusp as a potential new standard of care that doesn’t require IL-4R expression testing for efficacy.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna to Present Innovative Cancer Data at Conferences
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
TipRanks Canadian Auto-Generated NewsdeskMedicenna Announces Breakthroughs in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App